The startup, which currently focuses on liver tumors, will use the fresh $250 million investment from the deal to expand the applications of its ultrasound therapy devices to target growths in the breast, prostate, pancreas and other areas. HistoSonics is also accelerating its work targeting brain cancer.
Founded with research from University of Michigan scientists in 2009, HistoSonics says that sound waves can be an effective alternative to current ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.